Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roche's Tecentriq Shows 41% Reduction In Death Risk And 36% Lower Recurrence Risk In ctDNA-Guided Bladder Cancer Study

Author: Benzinga Newsdesk | October 20, 2025 01:37am
  • Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1
  • IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer
  • Data being presented as part of the Presidential Symposium at the ESMO Congress 2025

Posted In: RHHBF RHHBY RHHVF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist